174 related articles for article (PubMed ID: 15355928)
1. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.
Chung F; Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Tingle M; Ching LM
Clin Cancer Res; 2004 Sep; 10(17):5949-56. PubMed ID: 15355928
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide metabolites in mice and patients with multiple myeloma.
Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM
Clin Cancer Res; 2003 May; 9(5):1680-8. PubMed ID: 12738721
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans.
Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM
J Pharmacol Exp Ther; 2004 Aug; 310(2):571-7. PubMed ID: 15075384
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Scheffler MR; Colburn W; Kook KA; Thomas SD
Clin Pharmacol Ther; 1999 May; 65(5):483-90. PubMed ID: 10340913
[TBL] [Abstract][Full Text] [Related]
5. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Chung F; Wang LC; Kestell P; Baguley BC; Ching LM
Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
[TBL] [Abstract][Full Text] [Related]
6. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
7. [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients].
Li J; Luo S; Hong W; Zhou Z; Zou W
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):254-6. PubMed ID: 12515619
[TBL] [Abstract][Full Text] [Related]
8. Correspondence re: J. Lu et al., thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9: 1680-1688, 2003.
Zhou S
Clin Cancer Res; 2003 Nov; 9(14):5429; author reply 5429. PubMed ID: 14614031
[No Abstract] [Full Text] [Related]
9. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.
Chen TL; Vogelsang GB; Petty BG; Brundrett RB; Noe DA; Santos GW; Colvin OM
Drug Metab Dispos; 1989; 17(4):402-5. PubMed ID: 2571480
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
11. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits.
Adcock KG; Kyle PB; Deaton JS; Olivier JH; Hogan SM
Pharmacotherapy; 2007 Feb; 27(2):200-6. PubMed ID: 17253910
[TBL] [Abstract][Full Text] [Related]
16. Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Ho PC; Chan E; Duan W; Goh BC; Zhou S
J Pharm Biomed Anal; 2005 Sep; 39(1-2):299-304. PubMed ID: 16085147
[TBL] [Abstract][Full Text] [Related]
17. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
[TBL] [Abstract][Full Text] [Related]
18. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
19. Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice.
Dridi D; Ben-Attia M; Sani M; Djebli N; Sauvage FL; Boughattas NA
Chronobiol Int; 2008 Jul; 25(4):533-47. PubMed ID: 18622814
[TBL] [Abstract][Full Text] [Related]
20. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
